Maria Andersson

Articles

Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):748-756
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region
Andersson ML; Johansson H; Osterborg A; Mansson-Broberg A; Hansson L; Palma M
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Chen MS; Buggert M; Ingelman-Sundberg HM; Osterborg A
Article: HEMASPHERE. 2022;6(11):e794
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
Mulder TAA; Andersson MLL; Pena-Perez L; Heimersson K; Xagoraris I; Wahlin BE; Mansson R; Hansson L; Rassidakis G; Palma M

Doctoral thesis: 2026
Immunological and clinical effects of bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia
Andersson M
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2026;208(3):1116-1120
T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia
Andersson ML; Lind O; Heimersson K; Berglof A; del Peso Santos T; Pena-Perez L; Wang Q; Mulder TA; Zain R; Mansson R; Rosenquist R; Smith CIE; Osterborg A; Palma M

Affiliated to Research, Department of Oncology-Pathology, Karolinska Institutet, 2023-2026